Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | FEN1 | P39748 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074418 | 0.73 | PGR (0.43) | KDM1AMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL969980 | 0.72 | KDM1A (0.43) | KDM1AMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL15173501 | 0.72 | KDM1A (0.44) | KDM1AFEN1MAPK1PIK3CAMAPK8 | |
| SCHEMBL21484834 | 0.71 | ALDH1A1 (0.58) | KDM1ABACE1 | |
| SCHEMBL498595 | 0.71 | PGR (0.42) | KDM1AMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL527580 | 0.69 | KDM1A (1.00) | KDM1A | |
| SCHEMBL527581 | 0.69 | KDM1A (1.00) | KDM1A | |
| SCHEMBL15135731 | 0.69 | KDM1A (1.00) | KDM1A | |
| SCHEMBL5937169 | 0.69 | P4HA1 (0.56) | KDM1AMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL20924181 | 0.69 | KDM1A (0.68) | KDM1AMAPK1PIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100469770-C | 5-substituted-pyrazine or -pyridine glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | CN | disclosed |
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7132425-B2 | 5-substituted-six-membered heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1726197-A | 5-substituted-pyrazine or -pyridine glucokinase activators | HOFFMANN LA ROCHE (CH) | 2006-01-25 | — | — | CN | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | CHEN SHAOQING (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | GCK, GCKR, GALK1 | KDM1A 2594/4885FEN1 4364/4885ALOX5AP 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.